Company: OCEA
Filing Date: 2025-04-08
Form Type: 10-K
Source: 0001641172-25-003155
Chunk: 2580

Company: Ocean Biomedical, Inc.
Filing Date: 2025-04-08
Form: 10-K
Item: Item 1
Chunk 2580
---
 used appropriately.
However, we have not determined the specific allocation of any net proceeds among these potential uses, and the ultimate use of the net
proceeds may vary from the currently intended uses. The net proceeds may be used for corporate purposes that do not increase our operating
results or enhance the value of our securities.

The
amount of our future losses is uncertain and our quarterly operating results may fluctuate significantly or may fall below the expectations
of investors or securities analysts, each of which may cause our stock price to fluctuate or decline.

Our
quarterly and annual operating results may fluctuate significantly in the future due to a variety of factors, many of which are outside
of our control and may be difficult to predict, including the following:

    ●
    our
    ability to complete preclinical studies and successfully submit Investigational New Drug, or IND, applications or comparable applications
    for our product candidates;

    ●
    the
    timing and success or failure of preclinical studies and clinical trials for our product candidates or competing product candidates,
    or any other change in the competitive landscape of our industry, including consolidation among our competitors or partners;

    ●
    whether
    we are required by the FDA or similar foreign regulatory authorities to conduct additional clinical trials or other studies beyond
    those planned to support the approval and commercialization of our product candidates or any future product candidates;

    ●
    our
    ability to successfully recruit and retain subjects for clinical trials, and any delays caused by difficulties in such efforts;

    ●
    our
    ability to obtain marketing approval for our product candidates, and the timing and scope of any such approvals we may receive;

    ●
    the
    timing and cost of, and level of investment in, research and development activities relating to our product candidates, which may
    change from time to time;

    ●
    the
    cost of manufacturing our product candidates, which may vary depending on the quantity of production and the terms of our agreements
    with manufacturers;

    ●
    our
    ability to attract, hire and retain qualified personnel;

    ●
    expenditures
    that we will or may incur to develop additional product candidates;

    ●
    the
    level of demand for our product candidates should they receive approval, which may vary significantly;

    ●
    the
    risk/benefit profile, cost and reimbursement policies with respect to our product candidates, if approved, and existing and potential
    future therapeutics that compete with